Our products are available in 62 countriesClick here to learn more
Our activities incorporate all areas of the pharmaceutical value chainClick here to learn more
Innovation is one of the pillars of our strategy. We devote more than EUR 45 million to research and development.Click here to learn more
EMS (Environmental Management System) of EGIS-RUS successfully passed a certification audit for compliance with ISO 14001:2015 requirements. The audit was conducted by the International Organization for Standardization and Certification Bureau Veritas (Bureau Veritas Certification Rus JSC). Meeting the requirements of the ISO standards confirms the commitment of the management and employees to the highest requirements for climate protection and reduction of their environmental impact.
Egis launches in Russia a product with fixed-doses of atorvastatin and ezetimibe in one capsule for the treatment of hypercholesterolemia . Fixed-dose combination (FDC) developed by Egis will increase adherence in patients who take atorvastatin and ezetimibe separately, and a single dose per day should significantly simplify the drug therapy regimen.
The predecessor of Egis Pharmaceuticals PLC, Dr Wander Pharmaceuticals and Nutriments Ltd. was registered on 19 February 1913.
Please report any adverse events